MLTX · Insider Trading
MoonLake Immunotherapeutics Class A Ordinary Shares
Every open-market purchase and sale reported by MLTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-29 | Kristian Reich | Chief Scientific Officer | Sell | −1,100 | −$22.00K |
| 2026-07-23 | Kristian Reich | Chief Scientific Officer | Sell | −52,448 | −$1.05M |
| 2026-07-21 | Kristian Reich | Chief Scientific Officer | Sell | −43,700 | −$877.93K |
| 2026-07-20 | Kristian Reich | Chief Scientific Officer | Sell | −16,105 | −$322.26K |
| 2026-07-13 | da Silva Jorge Santos | Chief Executive Officer | Sell | −102,225 | −$2.05M |
| 2026-07-02 | da Silva Jorge Santos | Chief Executive Officer | Sell | −47,775 | −$956.93K |
| 2026-06-23 | Matthias Bodenstedt | Chief Financial Officer | Sell | −39,120 | −$862.20K |
| 2026-06-22 | BVF INC/IL | Director | A | — | — |
| 2026-06-18 | Catherine Moukheibir | Director | A | +22,195 deriv. | — |
| 2026-06-18 | Ramnik Xavier | Director | A | +22,195 deriv. | — |
| 2026-06-18 | Matthias Bodenstedt | Chief Financial Officer | Sell | −17,876 | −$351.58K |
| 2026-06-18 | Spike Loy | Director | A | +22,195 deriv. | — |
| 2026-06-18 | Andrew John Phillips | Director | A | +22,195 deriv. | — |
| 2026-06-17 | Kristian Reich | Chief Scientific Officer | Sell | −150,000 | −$2.85M |
| 2026-05-13 | Matthias Bodenstedt | Chief Financial Officer | Sell | −13,653 | −$273.33K |
| 2026-04-16 | Matthias Bodenstedt | Chief Financial Officer | Sell | −2,426 | −$47.45K |
| 2026-04-14 | da Silva Jorge Santos | Chief Executive Officer | Sell | −150,000 | −$2.75M |
| 2026-04-10 | Matthias Bodenstedt | Chief Financial Officer | Sell | −87,795 | −$1.66M |
| 2026-04-02 | BIOTECHNOLOGY VALUE FUND L P | Director | Sell | −3,750,000 | −$62.96M |
| 2026-01-09 | Kristian Reich | Chief Scientific Officer | A | +520,342 deriv. | — |
| 2026-01-09 | da Silva Jorge Santos | Chief Executive Officer | A | +520,342 deriv. | — |
| 2026-01-09 | Matthias Bodenstedt | Chief Financial Officer | A | +354,296 | — |
| 2025-12-22 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2025-12-22 | Matthias Bodenstedt | Chief Financial Officer | MIXED | — | — |
| 2025-12-22 | da Silva Jorge Santos | Chief Executive Officer | MIXED | — | — |
| 2025-12-10 | da Silva Jorge Santos | Chief Executive Officer | Sell | −200,000 | −$2.97M |
| 2025-12-10 | Kristian Reich | Chief Scientific Officer | Sell | −202,908 | −$3.01M |
| 2025-10-09 | Matthias Bodenstedt | Chief Financial Officer | Buy | +10,870 | +$98.81K |
| 2025-10-01 | Bihua Chen | — | Sell | −6,499,978 | −$46.87M |
| 2025-09-04 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2025-07-07 | Catherine Moukheibir | Director | MIXED | — | −$1.15M |
| 2025-06-09 | Ramnik Xavier | Director | A | +6,682 deriv. | — |
| 2025-06-09 | Andrew John Phillips | Director | A | +6,682 deriv. | — |
| 2025-06-09 | Simon Sturge | Director | A | +6,682 deriv. | — |
| 2025-06-09 | Spike Loy | Director | A | +6,682 deriv. | — |
| 2025-06-09 | Catherine Moukheibir | Director | A | +6,682 deriv. | — |
| 2025-06-09 | BIOTECHNOLOGY VALUE FUND II LP | Director | A | — | — |
| 2025-03-03 | Kristian Reich | Chief Scientific Officer | A | +139,273 deriv. | — |
| 2025-03-03 | Matthias Bodenstedt | Chief Financial Officer | A | +95,763 | — |
| 2025-03-03 | da Silva Jorge Santos | Chief Executive Officer | A | +95,763 | — |
| 2025-01-22 | Kristian Reich | Chief Scientific Officer | MIXED | — | — |
| 2024-10-08 | Simon Sturge | Director | Sell | −171,000 | −$9.19M |
| 2024-10-08 | BIOTECHNOLOGY VALUE FUND L P | Director | Sell | −2,000,000 | −$100.00M |
| 2024-06-10 | BVF PARTNERS L P/IL | Director | A | — | — |
| 2024-06-07 | Andrew John Phillips | Director | A | +7,688 deriv. | — |
| 2024-06-07 | Spike Loy | Director | A | +7,688 deriv. | — |
| 2024-06-07 | Simon Sturge | Director | A | +7,688 deriv. | — |
| 2024-06-07 | Ramnik Xavier | Director | A | +7,688 deriv. | — |
| 2024-06-07 | Catherine Moukheibir | Director | A | +7,688 deriv. | — |
| 2024-02-29 | da Silva Jorge Santos | Chief Executive Officer | Sell | −123,615 | −$6.80M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| BVF INC/IL | Director | 8,302,735 | $105.53M |
| Bihua Chen | 10%+ Owner | 8,190,943 | $104.11M |
| BIOTECHNOLOGY VALUE FUND II LP | Director | 8,168,838 | $103.83M |
| da Silva Jorge Santos | Chief Executive Officer | 2,843,182 | $36.14M |
| Kristian Reich | Chief Scientific Officer | 2,746,587 | $34.91M |
| Matthias Bodenstedt | Chief Financial Officer | 1,115,435 | $14.18M |
| BIOTECHNOLOGY VALUE FUND L P | Director | 1,039,238 | $13.21M |
| Simon Sturge | Director | 171,980 | $2.19M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MLTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.